BiotechTube

DYNE-101 + Placebo

Phase 3Recruiting
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myotonic Dystrophy Type 1 (DM1)

Conditions

Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease, Steinert

Trial Timeline

Apr 1, 2026 → Jan 1, 2029

NCT ID
NCT07486934

About DYNE-101 + Placebo

DYNE-101 + Placebo is a phase 3 stage product being developed by Dyne Therapeutics for Myotonic Dystrophy Type 1 (DM1). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07486934. Target conditions include Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT07486934Phase 3Recruiting
NCT05481879Phase 1/2Recruiting

Competing Products

16 competing products in Myotonic Dystrophy Type 1 (DM1)

See all competitors
ProductCompanyStageHype Score
TideglusibAMO PharmaPre-clinical
15
TideglusibAMO PharmaPhase 2
44
Tideglusib + PlaceboAMO PharmaPhase 2/3
57
TideglusibAMO PharmaPhase 2/3
57
VX-670Vertex PharmaceuticalsPhase 2
51
VX-670 + PlaceboVertex PharmaceuticalsPhase 1/2
40
SAR446268SanofiPhase 1/2
40
rhIGF-I/rhIGFBP-3 + placeboInsmedPhase 2
49
IONIS-DMPKRx + PlaceboIonis PharmaceuticalsPhase 1/2
38
Del-desiran (AOC 1001)Avidity BiosciencesPhase 3
74
ARO-DM1 Intravenous (IV) Infusion + Placebo Intravenous (IV) Infusion + ARO-DM1 subcutaneous (SC) injection + Placebo Subcutaneous (SC) InjectionArrowhead PharmaceuticalsPhase 1/2
38
DYNE-101 + PlaceboDyne TherapeuticsPhase 1/2
36
Pitolisant Oral Tablet + Placebo oral tabletHarmony BiosciencesPhase 2
47
PGN-EDODM1PepGenPhase 2
44
PGN-EDODM1PepGenPhase 2
44
PGN-EDODM1 for infusionPepGenPhase 1
25

Other Products from Dyne Therapeutics

DYNE-251 + PlaceboPhase 1/2
36
DYNE-101 + PlaceboPhase 1/2
36